ANCO’s ASCO Highlights 2019
ANCO's ASCO 2019 Update On PARP Inhibitors In Ovarian Cancer: Niraparib + Bevacizumab Improves PFS In Recurrent Ovarian Cancer & Olaparib Monotherapy Extends PFS In Germline BRCA1/2-mutated Ovarian Cancer
By
ANCO’s ASCO Highlights 2019
FEATURING
Rebecca Brooks
By
ANCO’s ASCO Highlights 2019
FEATURING
Rebecca Brooks
Comments 0
Login to view comments.
Click here to Login
